U.S. markets close in 2 hours 3 minutes

AcelRx Pharmaceuticals, Inc. (ACRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1200-0.0400 (-3.45%)
As of 1:57PM EDT. Market open.
Sign in to post a message.
  • S
    Stellar
    Once AGAIN, DSUVIA good Opioid Stewardship! Where is the NATIONAL NEWS on that?
    Thu, May 13, 2021
    "Data showed that patients in the SST group (DSUVIA) required 50% fewer opioids, with significantly more of them opioid-free (36% vs. 8%). Furthermore, SST-treated patients had improved overall benefit of analgesia scores compared to the control group."
    AS WE NOW KNOW: "The standard of care for perioperative opioid administration has not been disrupted for over 100 years." commented Dr. Pamela Palmer, AcelRx Chief Medical Officer and co-founder.
    MILESTONES coming up include five (5) Phase 4 studies pending... DZUVEO Europe partnership... NEW accelerated manufacturing line (reducing DSUVIA COSTS by 60%), etc.
    Bullish
  • j
    jack
    AcelRX earnings report is tomorrow. Perhaps a positive report will ignite an upward movement. ACRX has been napping for too long.
  • M
    Moneyy
    POSITIVE theme continues, with five (5) more Phase 4 studies pending from Cleveland Clinic, etc.
    Thu, May 13, 2021
    AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Grou
    Aug. 19, 2020
    AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA®
    - No Cognitive Impairment.
    - No Respiratory Depression.
    - 1 DSUVIA works on 100 pound patient or 300 pound patient, no dose adjustment.
    - DSUVIA reduced time in the PACU.
    - DSUVIA significant cost savings in the PACU.
    - DSUVIA is Good Opioid Stewardship.
    "Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting" by Christian Tvetenstrand, MD and Michael Wolff, MD, in the Journal of Clinical Anesthesia and Pain Management.
    https://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-publication-clinical-data
    AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA® | AcelRx Pharmaceuticals, Inc.
    ir.acelrx.com
    Bullish
  • C
    CodyT
    As the Rona fades it go time for Acrx. Did bashers make some money shorting. Sure. But they can come out of there mom basement and go pound sand now. Upward.
    Bullish
  • S
    Stellar
    Millions of Cancer Patients Suffer Needlessly From Pain
    February 02, 2019 08:10 AM
    Cancer is a leading cause of death globally. The World Health Organization reports there are more than 18 million new cases every year and 9.6 million deaths, most in low-or middle-income countries.

    MULTI-BILLION REVENUE POTENTIAL:
    ARX-02 (higher strength sufentanil sublingual tablets)
    A Phase 2 trial evaluating the efficacy and safety of ARX-02 (higher strength sufentanil sublingual tablets) for the treatment of cancer breakthrough pain in opioid-tolerant patients has been completed.
    https://acelrx.com/products/index.php
    AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain.
    AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain.
    acelrx.com
    Bullish
  • S
    Stellar
    May 13, 2021 (ACRX's contract manufacturer Catalent, BEST OF THE BEST)
    "Patient First" philosophy, which has been fundamental to our work developing and manufacturing so many COVID-19 vaccines and treatments for customers as part of the fight against the worldwide pandemic," commented John Chiminski, Chair and Chief Executive Officer of Catalent. He added, "I am incredibly proud that, throughout these most challenging of times, we have continued to prioritize the needs of people and patients, in line with our values and culture. This, our second corporate responsibility report, continues to formalize our progress in this area, supporting Catalent’s aim to be the world’s most trusted, reliable, and innovative drug development partner."
    Bullish
  • M
    Moneyy
    STAY TUNED!
    March 31, 2021
    Ms. Bozilenko has over 30 years of investment banking and other healthcare industry experience, including raising more than $30 billion in capital and executing numerous M&A transactions.

    "I'm excited to join AcelRx and contribute to its efforts to offer patients and healthcare providers a unique alternative to manage their patients' acute pain," said Marina Bozilenko. "I believe that AcelRx is well-positioned to leverage its existing commercial infrastructure and product portfolio to license or acquire complementary products to support its growth, and I look forward to contributing my corporate development and transactional experience to these growth efforts."
    https://finance.yahoo.com/news/acelrx-pharmaceuticals-announces-appointment-marina-123000223.html
    AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as
    AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as
    finance.yahoo.com
    Bullish
  • S
    Stellar
    How many of these patients could use a DSUVIA? Applied quickly, with NO IVs, NO needles, NO supplies, NO Respiratory Depression, NO Cognitive Impairment, etc. Acute Pain #1 reason people visit the ER:
    Common Reasons Why People Visit an Emergency Room
    Chest Pain. This is one of the top reasons why many people visit the ER because it's advised that anyone who has pain in the chest seek medical attention as soon as possible. ...
    Pain In The Abdomen. ...
    Aching Teeth. ...
    Bone And Ligament Issues. ...
    Respiratory Concerns. ...
    Cuts And Bruises. ...
    Pain In The Back. ...
    Infections.
    Bullish
  • C
    CH
    News Release

    Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting
    Bullish
  • S
    Stellar
    MILESTONES - 60% reduction in DSUVIA/DZUVEO per unit costs...DZUVEO EUROPE...
    April 28, 2021: "Catalent (CTLT, $20 billion) is our contract manufacturer that will operate the high volume packing line..." NOTE the milestones:
    March 15, 2021:
    "Importantly, this also clear the path to finalizing discussions on out-licensing DSUVIA or DZUVEO in Europe. We plan to have an agreement later this year with a potential partner for Europe."
    "I would like to provide a few other important updates before going into the financial review. First, our high-volume automated packaging line that has been held up in Europe because of COVID has finally shipped. We expect to receive the packaging line at our contract manufacturing facility by the end of the month."
    Bullish
  • J
    James
    Last chance to steal shares. Holding all of mine.
  • D
    Don Philippo
    Glad that I bought recently. You always have to find the beaten stocks. When earnings are great on Monday the next weeks can bring it over 1.3
  • S
    Stellar
    1y Target Est 6.67 (per Yahoo) avg analyst PT = almost 600% upside!
    Bullish
  • M
    Moneyy
    NO needles, NO IVs, NO Supplies, NO Respiratory Depression, NO Cognitive Impairment...
    https://www.youtube.com/watch?v=7TprgnuYfyQ
    7 months ago! (It took 10 years folks to get this win!)
    - DSUVIA now available to all branches of the military
    - Availability expanded beyond Milestone C approval for Army sets, kits and outfits
    AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment Formulary
    Sep 14, 2020
    REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the U.S. military's access to DSUVIA has been expanded with the addition of DSUVIA to the Department of Defense's Joint Deployment Formulary (JDF). The JDF is a core list of pharmaceutical products that are designated for deploying military units across all service branches.

    "DSUVIA's addition to the Joint Deployment Formulary continues to validate its importance as a key option in the treatment of acute pain and represents yet another significant milestone for AcelRx," said Vince Angotti, Chief Executive Officer at AcelRx Pharmaceuticals. "DSUVIA's advancement within the military coupled with recently published data showing how DSUVIA enhances recovery times in the post-operative setting supports the increasing momentum for DSUVIA use and allows more healthcare practitioners to experience DSUVIA's unique pharmacokinetic characteristics," stated Mr. Angotti.
    What’s Your Warrior? | Join Forces | GOARMY | Commercial
    www.youtube.com
    Bullish
  • m
    m
    Acrx has a good product so I don’t think it goes bankrupt anytime soon. The
  • m
    m
    Dsuvia is unique and effective. It is too bad it was approved so close to the COVID pandemic. The world medical community has been so busy fighting the virus. Doctors don’t have time for anything else. So the coolest painkiller in a generation has gone unnoticed. That will change soon. Investors who see this buy now when the price is so low and make a fortune in the near future. Dd as always.
  • F
    Felix
    All Dsuvia studies look terrific. US government beginning to stockpile the product, with military use in mind. Opioid addictions are reduced by this product. I could go on. However, physicians and dentists never heard of it. ACRX promotion = dead silence.
  • D
    Don Philippo
    I am in. This one is dirty cheap. It bottomed out at 1.10 and now all growth stock are gaining again. Some good news and this one is flying. You have to buy when everyone is fearful.

    Bought Plug at 20$ yesterday and sold at 23.5$ today. Quick 17.5% in one day. This will be my next money maker stock.

    I like buying beaten stocks. Just one good information and it takes off. Next Monday during the earnings call management will find some positive news. I am sure.
  • j
    joseph
    Still we have struggling volume. Although not dissatisfied with seeing green. In need of high volume.
  • J
    James
    More dilution!!!